WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018067548) PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/067548 International Application No.: PCT/US2017/054916
Publication Date: 12.04.2018 International Filing Date: 03.10.2017
IPC:
A61K 9/00 (2006.01) ,A61K 31/00 (2006.01)
Applicants: THE CHILDREN'S MEDICIAL CENTER CORPORATION[US/US]; 55 Shattuck Street Boston, Massachusetts 02115, US
DOMPE FARMACEUTICI S.P.A.[IT/IT]; Via San Martino 12-12/A 20122 Milan, IT
Inventors: FIORINA, Paolo; US
BASSI, Roberto; US
VERGANI, Andrea; US
ALLEGRETTI, Marcello; IT
Agent: MILLS, Tari W.; US
RESNICK, David S.; US
EISENSTEIN, Ronald I.; US
FITZGERALD, Mark J.; US
BENN, Susanna C.; US
BRAICH, Ravinderjit S.; US
CROSBY, David F.; US
HUFF, Shayne Y.; US
PTASHKA, Teresa A.; US
SUMMERFORD, Candace M.; US
KLING, Nicole D.; US
Priority Data:
62/403,36803.10.2016US
Title (EN) PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY
(FR) PRÉVENTION ET TRAITEMENT DE NÉPHROPATHIE DIABÉTIQUE
Abstract: front page image
(EN) Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
(FR) Des modes de réalisation de la présente invention concernent des méthodes se rapportant à la néphropathie diabétique; des méthodes pour prévenir l'apparition et également pour empêcher la progression de la néphropathie diabétique, ainsi que le traitement de la néphropathie diabétique chez des sujets diabétiques comprenant l'administration de réparixine et/ou de ladarixine, qui sont des inhibiteurs de l'activation des récepteurs CXCR1 et CXCR2 de CXCL8.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)